Events and Presentations Events and Presentations Past Events The JMP Securities Life Sciences Conference May 16, 2023 at 11:30 AM EDT Listen to webcast Supporting Materials JMP Securities Life Sciences Presentation 5.1 MB 22nd Annual Needham Virtual Healthcare Conference Apr 19, 2023 at 10:15 AM EDT Listen to webcast Supporting Materials View Presentation 5.1 MB Presentations JMP Securities Life Sciences Presentation May 2023 Corporate Presentation NextCure Trial in Progress Poster for NC525 at the 2022 ASH Annual Meeting SITC 2022 Poster - A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory or MSS/MSI-low ICI naïve advanced or metastatic solid tumors SITC 2022 Poster- A phase 1/2, open-label, dose-escalation, safety, and tolerability study of NC762 in subjects with advanced or metastatic solid tumors Tools
Events and Presentations Past Events The JMP Securities Life Sciences Conference May 16, 2023 at 11:30 AM EDT Listen to webcast Supporting Materials JMP Securities Life Sciences Presentation 5.1 MB 22nd Annual Needham Virtual Healthcare Conference Apr 19, 2023 at 10:15 AM EDT Listen to webcast Supporting Materials View Presentation 5.1 MB Presentations JMP Securities Life Sciences Presentation May 2023 Corporate Presentation NextCure Trial in Progress Poster for NC525 at the 2022 ASH Annual Meeting SITC 2022 Poster - A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory or MSS/MSI-low ICI naïve advanced or metastatic solid tumors SITC 2022 Poster- A phase 1/2, open-label, dose-escalation, safety, and tolerability study of NC762 in subjects with advanced or metastatic solid tumors
The JMP Securities Life Sciences Conference May 16, 2023 at 11:30 AM EDT Listen to webcast Supporting Materials JMP Securities Life Sciences Presentation 5.1 MB
22nd Annual Needham Virtual Healthcare Conference Apr 19, 2023 at 10:15 AM EDT Listen to webcast Supporting Materials View Presentation 5.1 MB
SITC 2022 Poster - A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory or MSS/MSI-low ICI naïve advanced or metastatic solid tumors
SITC 2022 Poster- A phase 1/2, open-label, dose-escalation, safety, and tolerability study of NC762 in subjects with advanced or metastatic solid tumors
